bluebird bio, Inc. (BLUE )

Currency in USD Disclaimer
$8.21 +$0.42 (5.41%)
Open 12/26/2024
$7.65
$8.35
$5.8
$38.4

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol BLUE
  • Company bluebird bio, Inc.
  • Price $8.21
  • Changes Percentage 5.41
  • Change 0.42
  • Day Low $7.65
  • Day High $8.35
  • Year High $38.4
  • Year Low $5.8
  • Market Cap $79,624,982
  • Price Avg 50 EMA (D) $8.5
  • Price Avg 200 EMA (D) $16.03
  • Exchange NASDAQ
  • Volume 118,498
  • Average Volume 422,111
  • Open $7.77
  • Previous Close $7.79
  • EPS -36
  • PE -0.23
  • Earnings Announcement 2025-03-24 12:30:00
  • Shares Outstanding $9,722,220

Company brief: BLUEBIRD BIO, INC. (BLUE )

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

BLUE Corporation News

Income Statement